US agency accuses L'Oreal of misleading marketing

September 12, 2012

US regulators accused French cosmetics giant L'Oreal of misleading claims in marketing its Lancome line of anti-aging products, according to a letter released Tuesday.

In the letter, addressed to the president of L'Oreal-owned Lancome USA, the said some Lancome products advertised online carry claims that "are intended to affect the structure or any function of the , rendering them drugs" under US law.

The products under scrutiny include the Genifique Youth Activating Concentrate, which claims to boost "the activity of genes and stimulates the production of youth proteins," according to the letter.

Another singled out is the Genifique Repair Youth Activating Night Cream, which claims to boost "the activity of ."

Lancome has 15 days to respond to the FDA warning with specific steps it has taken to correct the violations, according to the letter dated Friday.

"We request that you take prompt action to correct all violations associated with your products, including the violations identified in this letter," wrote the FDA's Michael W. Roosevelt of the Center for and Applied Nutrition. "Failure to do so may result in enforcement action without further notice."

L'Oreal is the world's largest cosmetics maker.

Related Stories

Recommended for you

Vaccinating against psoriasis, allergies and Alzheimer's a possibility, research shows

October 23, 2017
Research from the Universities of Dundee and Oxford has shown how combining the tetanus vaccine with a viral particle that normally affects cucumbers can be used to treat psoriasis and allergies, and may even protect against ...

Fighting opioid addiction in primary care—new study shows it's possible

October 18, 2017
For many of the 2 million Americans addicted to opioids, getting good treatment and getting off prescription painkillers or heroin may seem like a far-off dream.

With no morphine, 25 million die in pain each year: report

October 13, 2017
Every year, some 25 million people—one in ten of them children—die in serious pain that could have been alleviated with morphine at just a few cents per dose, researchers said Friday.

Study finds few restrictions on Rx opioids through Medicare

October 9, 2017
Medicare plans place few restrictions on the coverage of prescription opioids, despite federal guidelines recommending such restrictions, a new Yale study finds. The research results highlight an untapped opportunity for ...

Nocebo effect: Does a drug's high price tag cause its own side effects?

October 5, 2017
Pricey drugs may make people more vulnerable to perceiving side effects, a new study suggests—and the phenomenon is not just "in their heads."

Pre-packaged brand version of compounded medication to prevent preterm births costs 5,000 percent more

October 2, 2017
Preventing a preterm birth could cost as little as $200 or as much as $20,000, depending on which one of two medications a doctor orders, according to a new analysis from Harvard Medical School.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.